BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 37171599)

  • 21. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
    Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
    [No Abstract]   [Full Text] [Related]  

  • 22. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.
    Hirayama AV; Gauthier J; Hay KA; Voutsinas JM; Wu Q; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2019 Aug; 134(7):636-640. PubMed ID: 31648294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.
    Lu W; Wei Y; Cao Y; Xiao X; Li Q; Lyu H; Jiang Y; Zhang H; Li X; Jiang Y; Meng J; Yuan T; Zhu H; He X; Jin X; Sun R; Sui T; Liu K; Zhao M
    Cancer Immunol Immunother; 2021 Dec; 70(12):3501-3511. PubMed ID: 33899130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
    Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Milpied N; Fung H; Topp MS; Houot R; Beitinjaneh A; Peng W; Zheng L; Rossi JM; Jain RK; Rao AV; Reagan PM
    N Engl J Med; 2020 Apr; 382(14):1331-1342. PubMed ID: 32242358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
    Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
    Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.
    Wei G; Zhang Y; Zhao H; Wang Y; Liu Y; Liang B; Wang X; Xu H; Cui J; Wu W; Zhao K; Nagler A; Chang AH; Hu Y; Huang H
    Cancer Immunol Res; 2021 Sep; 9(9):1061-1070. PubMed ID: 34290048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.
    Zhu W; Tao S; Miao W; Liu H; Yuan X
    Front Immunol; 2022; 13():894787. PubMed ID: 35757723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of local reactions and efficacy of CD19 chimeric antigen receptor-modified T cells therapy in recurrent/refractory B-cell lymphoma with >7.5 cm lesions].
    Li Q; Deng HB; Liu MJ; Lyu CC; Zhu HB; Wang J; Jiang YL; Pu YD; Jiang YY; Li W; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):570-576. PubMed ID: 34455744
    [No Abstract]   [Full Text] [Related]  

  • 30. Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant.
    Li Q; Mu J; Yuan J; Yang Z; Wang J; Deng Q
    Onco Targets Ther; 2020; 13():11471-11484. PubMed ID: 33204102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis.
    Chen S; Zhang Y; Fang C; Zhang N; Wang Y; Chen R; Li Y; Tu S
    Crit Rev Oncol Hematol; 2022 Nov; 179():103807. PubMed ID: 36087853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.
    Muntañola A; Mozas P; Mercadal S; Huguet M; Bobillo S; Bastos-Oreiro M; Jiménez-Ubieto A; Rovira J; Rivero A; Tolosa C; Luizaga L; de Villambrosia SG; Novelli S; Caballero D; Salar A; Alonso-Álvarez S; Magnano L; Gutiérrez NC; Sancho JM; López-Guillermo A;
    Br J Haematol; 2023 Feb; 200(3):306-314. PubMed ID: 36261137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid response in relapsed follicular lymphoma with massive chylous ascites to anti-CD19 CAR T therapy using Piggy Bac: A case report.
    Zhang Y; Lin Z; Zhang F; Chen X; Yang Y; Fu X; Li Z; Sun Y; Qian Q
    Front Immunol; 2022; 13():1007210. PubMed ID: 36532014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy.
    Li T; Zhang Y; Peng D; Mao X; Zhou X; Zhou J
    J Immunother Cancer; 2019 Feb; 7(1):51. PubMed ID: 30791947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
    Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
    Front Immunol; 2021; 12():755866. PubMed ID: 34777368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
    Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
    J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells].
    Xiao X; Yuan T; Meng JX; Jiang YY; Cao YQ; Li Q; Sun R; Zhao MF
    Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(8):593-598. PubMed ID: 32164113
    [No Abstract]   [Full Text] [Related]  

  • 39. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
    Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
    Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma.
    Saha A; Jhaveri K; Sarfraz H; Chavez JC
    Expert Opin Biol Ther; 2023; 23(9):869-876. PubMed ID: 37599463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.